IngredientsDocosahexaenoic acid (DHA) is a long-chain, highly unsaturated omega-3 fatty acid. It is an important structural component of the human brain, cerebral cortex, skin, and retina, and is given the fatty acid notation 22:6(n−3). DHA is also known by the synonym cervonic acid and is formally described as a polyunsaturated fatty acid consisting of a chain of 22 carbon atoms with 6 cis double bonds at positions 4, 7, 10, 13, 16, and 19.
The full IUPAC name of DHA is (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid. In abbreviated scientific notation, DHA is designated C22:6n-3. DHA is considered a "long-chain" omega-3 because it contains 22 carbon atoms.
DHA is a long-chain, highly unsaturated omega-3 (n-3) fatty acid whose structure gives it unique physical and functional properties. Among unsaturated fatty acids present in substantial amounts in human tissues, it is the most unsaturated and longest one.
EPA and DHA are found in seafood, especially cold-water fish such as salmon, mackerel, and tuna, as well as shellfish and fish oil supplements. These fatty fish are by far the richest dietary sources of DHA, with each 75 g fish serving providing between 750 and 1,500 mg of EPA+DHA.
Breast milk also naturally contains DHA, and its concentration increases with higher maternal intakes of EPA+DHA. In organisms that do not eat algae containing DHA nor animal products containing DHA, DHA is instead produced internally from α-linolenic acid, a shorter omega-3 fatty acid manufactured by plants.
DHA is the most important and the most abundant n-3 PUFA in the brain, whereas only a small amount of EPA has been detected there. DHA levels are especially high in retina (eye), brain, and sperm cells.
DHA is metabolically related to other n-3 fatty acids; it can be synthesized from the plant essential fatty acid α-linolenic acid (ALA). However, this pathway does not appear to be very efficient in many individuals, although the conversion of ALA to DHA is much better in young women than in young men. Rates of DHA production in women are 15% higher than in men.
The biosynthesis of DHA is started from the dietary intake of eicosapentaenoic acid and docosapentaenoic acid. The primary action of DHA synthesis occurs by the activation of the elongation step with the help of the Δ4-desaturase enzyme, and an intermediate of C24 undergoes beta-oxidation in peroxisomes. This biosynthetic pathway is also known as "Sprecher's shunt" pathway.
Long-chain omega-3s are present in several dietary supplement formulations, including fish oil, krill oil, cod liver oil, and vegetarian products that contain algal oil. A typical fish oil supplement provides about 1,000 mg fish oil, containing 180 mg EPA and 120 mg DHA, but doses vary widely. Cod liver oil supplements provide vitamin A and vitamin D in addition to long-chain omega-3s.
There is also a variety of food products fortified with fish oil-derived EPA and DHA, including eggs, yogurt, milk, juice, and soy beverages. Fish oil supplements come in liquid, capsule, and pill form.
The story of DHA's discovery in a scientific context begins not with laboratory chemistry but with epidemiological observation of traditional dietary patterns among indigenous coastal peoples.
Danish researchers Bang and Dyerberg became intrigued by what seemed to be an outlier population — native Greenlanders who consumed whale and seal blubber and fatty fish as part of their daily diet. Back in the early 1970s the Inuit were still a hunter and fisherman society, living mostly on seal meat and fish; yet heart disease accounted for only 5.3% of deaths amongst Greenland males aged 45 to 64, compared to their US counterparts where 40% of deaths were due to coronary heart disease.
When Dyerberg and Bang analyzed 7-day food diaries and measured omega-3 intake, they found that EPA intake in the Inuit was much higher — in the neighborhood of two to two and a half grams a day — and the same for DHA, around two grams, so roughly 4–5 grams a day of EPA and DHA combined, compared to less than 1 gram a day in the Danes.
The "omega-3" story began with these seminal studies by Bang and Dyerberg in Greenland Inuits in the 1970s. The reduced risk for myocardial infarction among these native peoples was linked with higher dietary and blood omega-3 fatty acid levels, in particular EPA and DHA.
In the late 1970s, epidemiological studies revealed that Greenland Inuits had substantially reduced rates of acute myocardial infarction compared with Western control subjects, and these observations generated more than 4,500 studies to explore this and other effects of omega-3 fatty acids on human metabolism and health.
Following their stint in Greenland, the researchers published a landmark paper in The Lancet on July 15, 1978 entitled "Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?", presenting data supporting the idea that EPA from the seafoods consumed by these Inuit people could substitute for arachidonic acid in the cyclooxygenase pathway in platelets and reduce platelet "stickiness."
It is important to note, however, that the two researchers never formally proved that the Inuit had low rates of heart disease — they never tested it at all, relying on mortality statistics from regional health authorities. This methodological limitation has been acknowledged in later critical appraisals of the original observations, though the broad scientific impetus they provided proved highly productive.
Beyond the Greenland Inuit observations, the consumption of fatty fish and marine oils as traditional foods spans many cultures. Coastal Japanese, Scandinavian, and Mediterranean populations have historically consumed large quantities of oily fish. Prospective studies such as the Zutphen Study found that men who rarely or never ate fish had a higher rate of coronary heart disease compared with men who consumed fish one or more times per week, and the 30-year follow-up of the Western Electric Study confirmed these findings. Cod liver oil — a traditional Scandinavian preparation extracted from the livers of Atlantic cod — has been used for centuries in Northern European cultures as a remedy for rickets, joint pain, and general infirmity, providing among other nutrients both DHA and EPA alongside vitamins A and D.
Omega-3s are important components of the membranes that surround each cell in the body. As a component of neuronal membranes, the function of DHA is to support neuronal conduction and to allow the optimal functioning of neuronal membrane proteins such as receptors and enzymes. DHA is the major n-3 long-chain polyunsaturated fatty acid in brain gray matter, representing about 15% of all fatty acids in the human frontal cortex. DHA affects neurogenesis, neurotransmitter function, synaptic plasticity and transmission, and signal transduction in the brain.
One of the most significant and mechanistically important discoveries regarding DHA has been its enzymatic conversion into families of bioactive lipid mediators that actively resolve inflammation.
DHA is an omega-3 fatty acid playing a crucial regulatory role in the resolution of inflammation and acting as a precursor for the biosynthesis of the anti-inflammatory specialized pro-resolving mediators (SPMs) resolvins, protectins, and maresins. These metabolites exert many beneficial actions including neuroprotection, anti-hypertension, and anti-tumorigenesis. Dysregulation of SPMs is associated with diseases of prolonged inflammation.
Using an unbiased lipidomics and systems approach, Serhan and collaborators identified families of novel pro-resolving lipid mediators from DHA, including the D-series resolvins (RvD1, RvD2, RvD3, RvD4, RvD5, RvD6), the neuroprotectins/protectins (NPD1/PD1), and the maresins (MaR1).
The identification of resolvins, protectins, and maresins is of great importance, as these potent lipid mediators provide the first molecular basis for many of the health benefits attributed to DHA.
The term "resolvins" (resolution phase interaction products) was introduced to signify that these new structures were endogenous mediators possessing very potent anti-inflammatory and immunoregulatory actions, which include reducing neutrophil traffic, cytokine and reactive oxygen species regulation, as well as lowering the magnitude of the inflammatory response in vivo.
Omega-3 fatty acids including DHA are able to inhibit partly a number of aspects of inflammation including leucocyte chemotaxis, adhesion molecule expression and leucocyte-endothelial adhesive interactions, production of eicosanoids like prostaglandins and leukotrienes from the n-6 fatty acid arachidonic acid, production of inflammatory cytokines, and T cell reactivity.
Mechanisms underlying the anti-inflammatory actions of n-3 fatty acids include altered cell membrane phospholipid fatty acid composition, disruption of lipid rafts, inhibition of activation of the pro-inflammatory transcription factor nuclear factor kappa B — so reducing expression of inflammatory genes — and activation of the anti-inflammatory transcription factor NR1C3.
In the brain, DHA is a potential precursor to neuroprotective signaling pathways evoked by ischemia-reflow tissue injury. Given its potent actions to reduce neuroinflammation and protect neural cells, the metabolite 10,17-dihydroxy-protectin was coined neuroprotectin D1 (NPD1) when biosynthesized and acting in neural tissues and retinal epithelial cells. DHA is enriched in brain, synapses, and retina, where its protective role is appreciated, yet its role as a precursor to mediators in resolution and neuroprotection is still emerging.
In normal nervous tissue, the active lipid mediators of DHA — resolvins and neuroprotectins — control the duration and magnitude of inflammation partly through the inhibition of oxidative stress and apoptotic processes. Neuroprotectin D1 has been shown to up-regulate the anti-apoptotic proteins Bcl-2 and Bcl-xL and to decrease the expression of the pro-apoptotic proteins Bax and Bad in neurons and human retinal pigment epithelial cells.
Evidence strength: Moderate to strong for triglyceride reduction; mixed for hard cardiovascular endpoints; EPA monotherapy appears superior to EPA+DHA combinations for reducing major cardiovascular events.
A 2020 review of 23 studies (43,998 participants) showed that EPA and DHA reduce triglycerides by about 15% but do not affect body fat or other lipids. There is strong evidence that omega-3 fatty acids can significantly reduce blood triglyceride levels. There also appears to be a slight improvement in high-density lipoprotein (HDL, or "good") cholesterol, although an increase in levels of low-density lipoprotein (LDL, or "bad") cholesterol was also observed.
For broader cardiovascular endpoint reduction, the picture is more complex. A 2019 meta-analysis published in the Journal of the American Heart Association included data from 13 RCTs — including GISSI-Prevenzione, JELIS, Omega, Alpha Omega, ORIGIN, VITAL, ASCEND, and REDUCE-IT — with trials required to have a sample size of at least 500 patients and at least one year of follow-up. The total combined sample size was 127,477 participants, with a mean follow-up of 5 years.
The findings of this analysis showed that people who took daily omega-3 fish oil supplements, compared with those who took a placebo, lowered their risk for most cardiovascular outcomes except stroke, including an 8% reduced risk for heart attack and coronary heart disease death. The association was particularly evident at higher doses of omega-3 fish oil supplementation.
However, results from individual large trials have been heterogeneous. In ASCEND (A Study of Cardiovascular Events in Diabetes), which included 15,480 diabetes patients without existing CVD at baseline, marine omega-3 supplementation did not reduce the primary endpoint of serious vascular events. The VITAL (Vitamin D and Omega-3 Trial), which included 25,871 participants at "usual" risk of CVD from the general population, also did not find a statistically significant reduction in the primary endpoint of major CVD events. However, both ASCEND and VITAL found reductions in at least one prespecified secondary endpoint — vascular deaths in ASCEND and myocardial infarction in VITAL.
Conversely, REDUCE-IT showed a significant 25% relative reduction in the primary composite efficacy endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina (an absolute reduction of 4.8%) with icosapent ethyl — a highly purified ethyl ester of EPA — in patients with established ASCVD or those with high risk for ASCVD. Importantly, REDUCE-IT used EPA alone, not EPA+DHA.
Although results from individual RCTs have been inconsistent, meta-analyses aggregating data from multiple RCTs generally support a significant reduction in major cardiovascular events. Notably, EPA monotherapy appears more effective than combined EPA+DHA formulations, as evidenced by REDUCE-IT showing significant benefits from EPA-ethyl ester and STRENGTH being terminated early due to futility.
Several products containing omega-3s have been approved as prescription drugs to be used in combination with diet to reduce triglyceride levels in patients whose triglyceride levels are very high. The composition of these products is not the same as that of typical omega-3 supplements, and the testing and regulation of prescription drugs differ from those for dietary supplements; therefore, the effects of these prescription products may not be the same as those of omega-3 dietary supplements.
Evidence strength: Established role of DHA in brain and retinal structural development; clinical evidence for cognitive supplementation benefits is limited and inconsistent, though there is consistent evidence for reduced preterm birth risk.
DHA accumulates substantially in the retina and cerebral cortex during the last trimester and the second year of life. Intervention studies have shown that improving maternal DHA nutrition reduces the risk of impaired visual and neural development in infants and children.
In humans, the third-trimester placental supply of maternal DHA to the growing fetus is critically important as the growing brain obligatorily requires DHA during this window period. DHA is also involved in the early placentation process, essential for placental development.
A systematic review of the relationship between seafood consumption during pregnancy and child neurodevelopment concluded there was "moderate and consistent evidence" that consumption of commercially available seafood during pregnancy is associated with favorable offspring neurocognitive development. The conclusion was based on a review of 29 prospective cohort studies comprising 102,944 mother-child pairs.
Well-documented clinical benefits of maternal omega-3 fatty acid supplementation in pregnancy include reduced risks of early preterm birth (before 34 weeks gestation) and preterm birth generally.
Despite the biologically established importance of DHA for brain development, supplementation trials have not always translated this into measurable cognitive gains. DHA plays a crucial role in the growth and functional development of the infant brain; however, the impact of additional DHA supplementation on neurodevelopment in infants remains controversial in randomized controlled trials.
For example, one RCT supplementing mothers through pregnancy and lactation with 400 mg/d DHA did not impact offspring neurodevelopment at 12 months of age. A systematic review concluded there is "limited evidence" for a favorable effect of supplementation in pregnancy on cognitive outcomes and "insufficient evidence" to evaluate other developmental outcomes.
With respect to infant formula, the authors of a paper published by the American Academy of Family Physicians and of two Cochrane Reviews — one on full-term infants and one on preterm infants — have concluded that the evidence is insufficient to recommend the use of infant formulas supplemented with DHA and arachidonic acid.
Evidence strength: Preliminary to moderate for early-stage cognitive protection; insufficient for treating established Alzheimer's disease.
A 2022 review of 33 studies suggests that dietary and supplemental omega-3s may have a protective effect against cognitive decline for healthy people without preexisting Alzheimer's disease or dementia. However, there was no effect on cognition for people already diagnosed with Alzheimer's disease.
A 2018 review of 7 studies (795 participants) of men and women between the ages of 55 and 90 with mild to moderate Alzheimer's disease found that omega-3 fatty acid supplementation may be beneficial in disease onset, when there is slight impairment of brain function. The authors said there is not enough evidence to support omega-3 fatty acid supplementation for treatment of established disease.
A 2017 research review suggested that people who carry a gene called APOE4, which is associated with an increased risk of Alzheimer's disease, might benefit from taking DHA before developing signs of the disease.
In adults, whereas n-3 LCPUFA supplementation has led to some improvement in individuals with mild cognitive impairment, data are inconsistent as to whether they can be beneficial in older adults with health conditions impacting the brain and eye, such as dementia and Alzheimer's disease or macular degeneration.
Evidence strength: Weak to mixed; uncertain clinical relevance; preliminary evidence for antenatal depression.
Although some studies have had promising results, it is uncertain whether omega-3 fatty acid supplements are helpful for depression. A 2021 review of 35 studies (1,964 participants) reaffirmed the conclusion from a 2015 review that if there is an effect, it may be too small to be meaningful.
In a 2019 review of the effects of omega-3s on mental health during pregnancy and postpartum, 9 out of 14 studies (3,543 participants) showed that high consumption of DHA, either alone or with other fatty acids, may reduce symptoms of depression and anxiety during gestation. However, none of the studies showed omega-3s had an effect on depression or anxiety during the postpartum period. The authors recommend further research.
With respect to the relative role of DHA specifically versus EPA, according to some meta-analyses and randomized controlled trials, DHA supplements have not shown efficacy in improving symptoms of depression compared to EPA. However, a meta-analysis by Chang et al. showed that supplementing with DHA is more effective than EPA in improving depressive symptoms in elderly dementia patients. For patients with depression, lower doses of DHA (i.e., 1 g/d) may be more effective than higher doses (2 or 4 g/d), though this phenomenon is difficult to explain.
Evidence strength: Weak; conflicting results; no definitive clinical recommendation.
There is some evidence that ADHD could be related to lower dietary intake of omega-3 and higher dietary intake of omega-6 fatty acids. However, research on omega-3 supplements for ADHD has had conflicting results. It is uncertain whether omega-3s have any benefit for symptoms of this condition.
Evidence strength: Observational evidence of association; limited RCT evidence for disease modification.
DHA levels are especially high in the retina. Observational studies have noted that fish-consuming populations have lower rates of age-related macular degeneration (AMD). However, once someone has AMD, taking omega-3 supplements does not keep the disease from getting worse or slow down vision loss.
Evidence strength: Strong; well-established and FDA-recognized at pharmacologic doses.
There is strong evidence that omega-3 fatty acids can significantly reduce blood triglyceride levels, with a slight improvement in HDL cholesterol, though an increase in LDL was also observed. The U.S. Food and Drug Administration recommends consuming no more than 3 g/day of EPA and DHA combined, including up to 2 g/day from dietary supplements. Higher doses are sometimes used to lower triglycerides, but these doses could cause bleeding problems and possibly affect immune function.
Evidence strength: Modest; consistent signal for symptomatic relief, not disease modification.
Studies suggest fish oil supplements might help reduce pain, improve morning stiffness, and relieve joint tenderness in people with rheumatoid arthritis. While relief is often modest, it might be enough to reduce the need for anti-inflammatory medications.
Evidence strength: Moderate; consistent evidence for reduction in preterm birth.
Well-documented clinical benefits of maternal omega-3 fatty acid supplementation in pregnancy include reduced risks of early preterm birth (before 34 weeks of gestation) and preterm birth overall. Although recent systematic reviews and meta-analyses have failed to report a consistent beneficial effect of higher DHA intakes on cognitive and visual function early in life, most reported a beneficial effect on gestational length and infant birth weight.
Long-chain omega-3s are present in several dietary supplement formulations, including fish oil, krill oil, cod liver oil, and vegetarian algal oil. A typical fish oil supplement provides about 1,000 mg fish oil, containing 180 mg EPA and 120 mg DHA, but doses vary widely.
Commonly reported side effects of omega-3 supplements are usually mild. These include unpleasant taste, bad breath, heartburn, nausea, gastrointestinal discomfort, diarrhea, headache, and odoriferous sweat.
The theoretical concern that omega-3 supplementation at typical doses increases clinically significant bleeding has been extensively examined. A systematic review and meta-analysis of 120,643 patients from 11 randomized clinical trials found no statistically significant difference in pooled bleeding events among patients receiving omega-3 PUFAs and those in the control group. Likewise, the incidence of hemorrhagic stroke, intracranial bleeding, and gastrointestinal bleeding were similar. However, a prespecified analysis in patients receiving high-dose purified EPA demonstrated a 50% increase in relative risk of bleeding but only a modest increase in absolute risk (0.6%) compared with placebo.
Adverse effects of omega-3 fatty acid supplements may include new-onset atrial fibrillation and increased propensity for bleeding. Drug interactions may exist with aspirin or clopidogrel (Plavix).
The relationship between omega-3 supplementation and atrial fibrillation (AF) risk is dose-dependent and biologically nuanced. This relationship is dose-dependent: DHA+EPA doses of approximately 1,000 mg/d increased AF risk approximately 12%, whereas 1,800 to 4,000 mg/d increased AF risk by approximately 50%.
A meta-analysis of omega-3 and AF showed that high doses of omega-3 (2–4 g/d of EPA or combined EPA and DHA) increase the risk of AF by 51%, whereas low doses (1 g/d or less) have little to no effect on AF risk.
In contrast, observational studies focused on DHA+EPA blood levels or dietary intake have generally reported that higher omega-3 levels/consumption are associated with lower AF risk. Other studies have indicated that omega-3 fatty acids can dose-dependently increase vagal tone, which could explain this biphasic relationship, as experimental studies show that low-level vagal stimulation decreases risk of AF whereas high-level vagal stimulation increases it.
Although seafood contains varying levels of methyl mercury (a toxic heavy metal), omega-3 supplements have not been found to contain this contaminant because it is removed during processing and purification.
Individuals with an unknown allergy to fish or shellfish may experience an anaphylactic reaction to fish oil supplements.
Most evidence for the health benefits of n-3 long-chain PUFAs is based on studies of fish consumption and/or fish oil supplementation that contain both EPA and DHA in different proportions. Therefore, relatively little is known about the unique effects of DHA alone (i.e., without confounding effects of dietary EPA) on health outcomes.
Health conditions that Docosahexaenoic acid may help support.
DHA and EPA both reduce F2-isoprostanes (a validated oxidative stress biomarker) in RCTs, interpreted as a reduction in systemic oxidative stress. DHA metabolites (including protectins/neuroprotectins) protect neural tissue from oxidative injury. DHA combined with vitamin D shows higher antioxidant and protective action in preterm infant studies.
DHA, alongside EPA, modulates neuronal membrane properties, receptor expression, and neurotransmission in ways that may reduce anxiety symptoms. Meta-analyses of RCTs show mixed but generally positive signals for omega-3 PUFAs on anxiety. DHA's anxiolytic potential is supported by its anti-inflammatory and pro-resolving activity in the brain. EPA appears to have a larger independent anxiolytic effect, though DHA contributes mechanistically.
DHA has been associated with reduced coronary atherosclerosis progression in observational studies, and improves endothelial function, platelet activity, and wall shear stress in experimental and clinical data. Higher circulating DHA levels correlate with reduced risk of sudden cardiac death. Animal models show a 4-fold reduction in atherosclerotic lesion burden with DHA feeding.
DHA and EPA reduce joint inflammation in arthritis by lowering pro-inflammatory eicosanoid synthesis and pro-inflammatory cytokine production (TNF-α, IL-1β). Omega-3s including DHA are recognized for managing rheumatoid arthritis, with anti-inflammatory properties documented in systematic reviews. Clinical evidence demonstrates modest reductions in joint pain and stiffness with EPA+DHA supplementation.
DHA and EPA exert anti-inflammatory effects in the lungs by modulating eicosanoid pathways, reducing leukotriene synthesis relevant to bronchoconstriction and airway inflammation. Omega-3s including DHA are recognized as potentially beneficial for managing asthma through their anti-inflammatory properties. Maternal omega-3 supplementation during pregnancy may protect children from developing allergies and asthma.
DHA is depleted in children with ADHD relative to typically developing peers. RCT evidence for DHA alone in ADHD is mixed—one double-blind RCT found no significant benefit at 345 mg/day—but combined EPA+DHA supplementation shows more promise for improving attention and behavior. DHA's structural role in brain development and neurotransmission underpins its mechanistic relevance.
Docosahexaenoic acid dose-dependently inhibits platelet aggregation and reduces αIIbβ3 integrin expression on platelet membranes. It is incorporated into platelet phospholipids where it alters membrane fluidity and reduces activation responses. Evidence includes in vitro studies, RCTs of combined EPA/DHA supplementation, and systematic reviews.
DHA supplementation consistently lowers systolic and diastolic blood pressure in RCTs, with DHA showing greater antihypertensive effect than EPA. The mechanism involves reduction of wall shear stress, IL-1β suppression, and improved vascular endothelial function. Clinical trials report moderate but statistically significant blood pressure reductions with algal DHA.
DHA content in breast milk is directly and positively correlated with maternal DHA intake. Supplementation during lactation reliably increases breast milk DHA concentrations, benefiting infant neurodevelopment and retinal maturation. DHA is considered a critical nutrient during breastfeeding, with international consensus supporting maternal supplementation.
DHA reproducibly lowers triglycerides (with a greater effect than EPA), raises HDL-2 cholesterol, and raises LDL cholesterol concentration while shifting LDL to a larger, less atherogenic particle size. Total cholesterol is largely unchanged. These lipid effects have been confirmed in multiple systematic reviews and RCTs using algal and fish-oil DHA.
DHA exerts well-documented anti-inflammatory effects via modulation of inflammatory gene expression, reduction of pro-inflammatory cytokines, and generation of pro-resolving mediators (resolvins, protectins). Systematic reviews of RCTs confirm DHA lowers F2-isoprostanes (a marker of oxidative stress) and promotes an anti-inflammatory oxylipin profile. These effects underlie DHA's relevance to many chronic inflammatory conditions.
DHA is the dominant structural omega-3 in the brain and is inversely associated with cognitive decline in observational studies. Multiple clinical trials in adults with mild cognitive impairment show variable but generally positive effects on episodic memory and attention. Trial data for Alzheimer's disease prevention have been largely negative at conventional doses, with bioavailability to the brain as a limiting factor.
Multiple clinical trials and meta-analyses support omega-3 PUFAs, including DHA, in reducing depressive symptoms, though EPA appears more efficacious as a standalone agent. A double-blind dose-finding pilot RCT found significant HAM-D reductions with 1–2 g/day DHA. A meta-analysis of 26 RCTs (n=2160) demonstrated an overall beneficial effect of omega-3 PUFAs on depression (SMD=−0.28, P=0.004). DHA contributes through modulation of serotonin, dopamine, and the HPA axis.
DHA and EPA modulate ocular surface inflammation through eicosanoid pathways, shifting the balance toward anti-inflammatory mediators. DHA plays an active role in organizing the lacrimal lipid film, reducing tear evaporation and improving Meibomian gland lipid secretion. Phase 3 clinical trials have been conducted for EPA+DHA supplementation in dry eye disease.
DHA is the principal polyunsaturated fatty acid in human sperm membranes and is critical for sperm motility, vitality, and morphology. DHA is significantly reduced in idiopathic infertile men compared to fertile controls. Dietary DHA supplementation improves seminal antioxidant status and decreases sperm DNA fragmentation in clinical trials.
DHA supports brain development pathways relevant to attention and learning in children. The DOLAB I RCT found 600 mg/day algal DHA for 16 weeks improved behavior and learning in under-performing children aged 7–9. Crossover RCT data suggest increasing erythrocyte DHA+EPA may improve attention and behavior in children with ADHD, though DHA-only RCTs in ADHD have been negative.
DHA's structural role in brain membrane phospholipids supports neural signaling efficiency, with beneficial associations with attention and concentration in observational and intervention studies. The effect is most documented in children with low DHA status and adults with memory complaints. DHA's role in supporting general cognitive processing speed and attention is supported by mechanistic and some clinical evidence.
DHA is the dominant structural fatty acid in the retina, essential for the function of photoreceptor rod cells. DHA deficiency impairs visual acuity and retinal function. DHA is rapidly accumulated in retinal tissue prenatally and in early postnatal life. Clinical evidence supports DHA supplementation for maintaining visual function in infants and potentially in age-related conditions.
DHA supplementation modulates gut microbiota composition, increasing beneficial bacteria and promoting metabolic pathways linked to carbohydrate and energy metabolism. Maternal DHA supplementation during lactation alters offspring gut microbiome. DHA's gut microbiome effects may mediate some of its neurological benefits via the gut-brain axis.
DHA supports multiple aging-related biological systems: it reduces cardiovascular risk factors, supports cognitive function, maintains neural membrane integrity, and exerts anti-inflammatory and antioxidant effects that may slow age-related cellular deterioration. Observational data link higher DHA status with reduced all-cause mortality and better quality of life in older adults.
DHA is essential for optimal nervous system and visual system maturation from the prenatal period through early childhood. It is required for neurogenesis, synaptogenesis, myelination, and retinal photoreceptor function. Adequate DHA in early life is associated with improved cognitive and visual outcomes in infants and young children.
Extensive epidemiological and interventional evidence supports DHA's cardioprotective effects, principally through triglyceride reduction, HDL improvement, blood pressure and heart rate lowering, and platelet function modulation. The landmark GISSI-Prevenzione trial showed significant reduction in cardiovascular death with EPA+DHA supplementation post-MI. DHA specifically demonstrates a somewhat greater triglyceride-lowering and heart-rate-lowering effect than EPA.
DHA demonstrably reduces resting heart rate and modulates heart rate variability (HRV) in clinical studies, effects considered favorable for cardiac autonomic health. Multiple RCTs show DHA is more effective than EPA at lowering heart rate. However, at high doses, omega-3 supplementation has been associated with increased atrial fibrillation (AF) risk.
DHA demonstrates anti-inflammatory and mucosal protective effects in experimental colitis models, reducing pro-inflammatory cytokines, oxidative stress, and improving intestinal barrier function. A large prospective cohort study (n=229,702 from 9 European centers) found high dietary DHA intake inversely associated with Crohn's disease incidence.
DHA has shown inconsistent effects on glycemic control in RCTs. A USDA-funded RCT in hypertriglyceridemic men found DHA improved lipocentric but not glucocentric markers of insulin sensitivity. DHA and EPA have been shown to differentially alter gut microbiota and may reverse high-fat diet-induced insulin resistance in animal models, though human RCT evidence is mixed.
DHA is essential for brain structure and function relevant to learning. The DOLAB I RCT found 600 mg/day algal DHA improved behavior and learning in under-performing school-age children. Observational data in adults link higher DHA status with better learning-related cognitive performance. DHA supports neurogenesis, synaptic plasticity, and neurotransmitter function underpinning learning.
DHA intake is inversely associated with advanced AMD in several large prospective cohort studies. The NAT2 RCT found DHA+EPA supplementation did not significantly reduce AMD progression overall, but patients maintaining a consistently high EPA+DHA index showed significantly reduced choroidal neovascularization. The AREDS2 trial (DHA+EPA for 5 years) also did not slow progression to advanced AMD. Evidence is mixed but supports a role for high DHA status.
DHA is an integral component of neural membrane phospholipids and is positively associated with memory performance in observational and clinical data. A meta-analysis of RCTs found that DHA/EPA supplementation (>1 g/day) significantly improved episodic memory in adults with memory complaints. Results are most consistent in adults with existing memory deficits rather than in cognitively intact individuals.
DHA addresses multiple components of metabolic syndrome simultaneously: it lowers triglycerides, raises HDL cholesterol, reduces blood pressure, decreases oxidative stress, and has anti-inflammatory effects. A USDA RCT in hypertriglyceridemic men found DHA supplementation improved fasting and postprandial lipid profiles relevant to metabolic syndrome.
DHA is a major structural component of peripheral and central nerve cell membranes, supporting axonal conduction and myelin integrity. DHA deficiency alters neuronal membrane composition including myelin and synaptosomes. DHA's anti-inflammatory and neuroprotective properties are relevant to peripheral neuropathy prevention and management.
DHA directly supports neuroplasticity by promoting neurogenesis, synaptogenesis, and synaptic connectivity in the brain. It improves myelination, modulates dendritic branching, and enhances hippocampal neurotrophic signaling. Lipidomics studies confirm DHA from various sources improves prefrontal cortex synaptic plasticity through membrane lipid composition changes.
DHA modulates monoamine neurotransmitter systems in the brain. Animal studies show DHA supplementation significantly increases hypothalamic serotonin, 5-HIAA (serotonin metabolite), and dopamine. DHA also affects HPA axis hormones (corticosterone, ACTH) and arginine vasopressin, with implications for mood, stress response, and neurotransmitter homeostasis.
DHA levels decline substantially in mothers during pregnancy and lactation as DHA is transferred to the fetus and neonate. DHA supplementation in the postpartum period supports maternal mood (reducing postpartum depression risk), replenishes depleted maternal stores, and maintains breast milk DHA content for ongoing infant development.
DHA is a critical structural nutrient for fetal brain and retinal development, accumulating rapidly in neural and retinal tissue during the third trimester. Maternal DHA supplementation is associated with improved infant neurodevelopment and visual acuity. International guidelines recommend 200 mg/day DHA from mid-pregnancy.
DHA and EPA reduce symptoms in inflammatory skin diseases including psoriasis by limiting the inflammatory process via 15-lipoxygenase pathways. A small non-blinded clinical study found adjunctive omega-3 supplementation (640 mg/day EPA+DHA) beneficial for mild-to-moderate plaque psoriasis. Omega-3s have strong anti-inflammatory effects on skin cells and can improve some skin conditions including psoriasis.
Docosahexaenoic acid (DHA) from marine oils reduces pro-inflammatory eicosanoids and generates anti-inflammatory resolvins D relevant to RA. Combined with EPA, it is among the most evidence-supported natural interventions for RA, with multiple RCTs and meta-analyses demonstrating reduced joint tenderness, morning stiffness, and NSAID use.
Omega-3 PUFAs including DHA have been studied in seasonal and broader mood disorders. Lower omega-3 status correlates with more severe seasonal affective disorder symptoms in observational data. DHA's effects on serotonin, neuroinflammation, and HPA axis regulation provide a mechanistic basis for seasonal mood support.
Docosahexaenoic acid (DHA) is a long-chain omega-3 fatty acid from marine sources with well-established triglyceride-lowering effects. At therapeutic doses (2–4 g/day combined EPA+DHA), DHA contributes to 20–50% TG reductions confirmed in multiple RCTs and FDA-approved combination omega-3 drugs.
Body systems that Docosahexaenoic acid may help support.
Go back